On Friday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened lower -3.01% from the last session, before settling in for the closing price of $293.69. Price fluctuations for ALNY have ranged from $141.98 to $304.39 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 97.61%. Company’s average yearly earnings per share was noted 35.91% at the time writing. With a float of $127.23 million, this company’s outstanding shares have now reached $128.38 million.
The extent of productivity of a business whose workforce counts for 2100 workers is very important to gauge. In terms of profitability, gross margin is 87.0%, operating margin of 4.38%, and the pretax margin is -2.63%.
Alnylam Pharmaceuticals Inc (ALNY) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Alnylam Pharmaceuticals Inc is 0.90%, while institutional ownership is 94.01%. The most recent insider transaction that took place on Aug 20 ’24, was worth 4,200,000. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $280.00, taking the stock ownership to the 73,441 shares. Before that another transaction happened on Aug 20 ’24, when Company’s Officer proposed sale 15,000 for $280.00, making the entire transaction worth $4,200,000.
Alnylam Pharmaceuticals Inc (ALNY) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 35.91% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Check out the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). In the past quarter, the stock posted a quick ratio of 2.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.60. Likewise, its price to free cash flow for the trailing twelve months is 114.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.60, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
The latest stats from [Alnylam Pharmaceuticals Inc, ALNY] show that its last 5-days average volume of 0.84 million was inferior to 0.87 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 41.17%. Additionally, its Average True Range was 7.62.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 87.57%, which indicates a significant increase from 50.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.69% in the past 14 days, which was lower than the 59.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $274.54, while its 200-day Moving Average is $204.04. Now, the first resistance to watch is $291.14. This is followed by the second major resistance level at $297.42. The third major resistance level sits at $301.10. If the price goes on to break the first support level at $281.18, it is likely to go to the next support level at $277.50. The third support level lies at $271.22 if the price breaches the second support level.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
There are currently 126,492K shares outstanding in the company with a market cap of 36.57 billion. Presently, the company’s annual sales total 1,828 M according to its annual income of -440,240 K. Last quarter, the company’s sales amounted to 659,830 K and its income totaled -16,890 K.
